These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8983284)

  • 61. A randomized comparative study of antiemetic prophylaxis with ondansentron in a single 32-mg loading dose versus 8 mg every 6 h in patients undergoing cisplatin-based chemotherapy.
    Tsavaris N; Fountzilas G; Mylonakis N; Athanassiadis A; Kosmas C; Karakousis C; Bacoyiannis C; Kosmidis P
    Oncology; 1998; 55(6):513-6. PubMed ID: 9778615
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group.
    Clavel M; Bonneterre J; d'Allens H; Paillarse JM
    Eur J Cancer; 1995; 31A(1):15-9. PubMed ID: 7695971
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
    Rapoport BL
    Curr Med Res Opin; 2014 Sep; 30(9):1875-81. PubMed ID: 24911369
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
    Holdsworth MT; Raisch DW; Duncan MH; Chavez CM; Leasure MM
    Ann Pharmacother; 1995 Jan; 29(1):16-21. PubMed ID: 7711340
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
    De Mulder PH; Seynaeve C; Vermorken JB; van Liessum PA; Mols-Jevdevic S; Allman EL; Beranek P; Verweij J
    Ann Intern Med; 1990 Dec; 113(11):834-40. PubMed ID: 2146911
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
    Ng WL; Della-Fiorentina SA
    Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients.
    Stewart A; McQuade B; Cronje JD; Goedhals L; Gudgeon A; Corette L; Froger X; Tubiana-Hulin M; Laplaige P; Roberts JT
    Oncology; 1995; 52(3):202-10. PubMed ID: 7715904
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
    Zeng WY
    Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):273-5. PubMed ID: 1396075
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
    Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
    J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ondansetron reduces nausea and vomiting after paediatric adenotonsillectomy.
    Morton NS; Camu F; Dorman T; Knudsen KE; Kvalsvik O; Nellgard P; Saint-Maurice CP; Wilhelm W; Cohen LA
    Paediatr Anaesth; 1997; 7(1):37-45. PubMed ID: 9041573
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
    Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1891-903. PubMed ID: 1387775
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
    Harousseau JL
    Bull Cancer; 1996 Jan; 83(1):71-76. PubMed ID: 8672859
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Single dose intravenous ondansetron for the 24-hour treatment of postoperative nausea and vomiting.
    Claybon L
    Anaesthesia; 1994 Jan; 49 Suppl():24-9. PubMed ID: 8129159
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group.
    Noble A; Bremer K; Goedhals L; Cupissol D; Dilly SG
    Eur J Cancer; 1994; 30A(8):1083-8. PubMed ID: 7654434
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A review of ondansetron in the management of radiotherapy-induced emesis.
    Roberts JT; Priestman TJ
    Oncology; 1993; 50(3):173-9. PubMed ID: 8459988
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2.
    Kris MG; Clark RA; Tyson LB; Hahne WF; Pisters KM; Gralla RJ
    Am J Clin Oncol; 1993 Feb; 16(1):77-80. PubMed ID: 8424410
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy.
    Franzén L; Nyman J; Hagberg H; Jakobsson M; Sorbe B; Nyth AL; Lomberg H; Henriksson R
    Ann Oncol; 1996 Aug; 7(6):587-92. PubMed ID: 8879372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.